The New Jersey Economic Development Authority is accepting applications for New Jersey Innovation Fellows Program Cohort III. Applications opened September 9, 2026 and must be submitted by December 4, 2026 at 5:00 PM EST through the NJEDA online application portal.
Funding and award structure
NJEDA states that Cohort III is supported by a remaining allocation of $2.5 million. Subject to available funding, up to six highest-scoring applications are expected to be recommended for awards, with a possible seventh award if funds remain. Each team may receive a $200,000 base grant plus up to $200,000 in bonuses, for a maximum potential award of $400,000 per team. The grant term is 24 months and funds are restricted to income replacement through payroll and related payroll expenses for the approved entrepreneur team.
Eligibility and required application materials
The applicant is a prospective startup idea led by a team of at least three full-time entrepreneurs. At least half of the leadership team must qualify as first-time entrepreneurs under NJEDA rules, the team must hold majority equity in the proposed venture, and all entrepreneur leaders must satisfy recent New Jersey gross income tax requirements and commit to the program’s full-time and two-year mentorship obligations. The proposed venture must operate in an NJEDA Targeted Industry and be located in an eligible New Jersey municipality. Life Sciences is an expressly listed Targeted Industry.
Applications must include all required online questions and PDF attachments, including a business plan of up to 3,000 words, a pitch deck limited to 15 slides, an organizational chart, and resumes for each entrepreneur leader, together with the required eligibility documentation. NJEDA charges a $250 non-refundable application fee. The controlling NOFA does not identify a non-Federal match requirement.
Atlas analysis
Atlas Opportunity Score: 93/100. This is a current, well-documented, competitive New Jersey innovation grant with substantial per-team support, a long application runway, and express Life Sciences eligibility. N9+ Fit Score: 20/100. A newly forming Life Sciences venture could conceptually build around technology related to remote diagnostics, but NJIF funds are restricted to entrepreneur income replacement and cannot be treated as equipment or device-purchase funding. Existing Dr. Miltie/QC Healthcare operations are not established as eligible because Cohort III is designed for prospective ventures led by qualifying entrepreneur teams, including first-time entrepreneur requirements. No direct application or outreach should be initiated without independently verifying a genuinely eligible new team and venture.